Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. - Wikidata - wikimedia - TriplyDB

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

http://www.wikidata.org/entity/Q38892734

about

Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer The STAMPEDE trial: paradigm-changing data through innovative trial design.MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Cabozantinib in the treatment of hepatocellular carcinoma.Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Cabozantinib in genitourinary malignancies.Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.Effective combinatorial immunotherapy for castration-resistant prostate cancer Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.Integrating phosphoproteomics into the clinical management of prostate cancer Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.Modulation of cabozantinib efficacy by the prostate tumor microenvironment.Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.Bone-Targeted Therapies in Cancer-Induced Bone Disease.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy.Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.Attaining precision therapy in prostate cancer: A tall order.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.Vitamin D in prostate cancer.Next Generation Sequencing in metastatic castrate-resistant prostate cancer.Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation

P2860

Q28067777-752015D6-1819-416E-90B0-FE1AA74E393E Q36163344-E1C3DB90-9264-4050-8D7B-018F68021C6B Q37597858-A42122F9-74AB-46E5-8005-904D23623090 Q37672483-A5181913-B249-477C-AD28-9E76E74F9C50 Q38658285-ED385A76-DBF4-4B72-8F76-8FAD08B22F80 Q38678038-8469C582-DEFB-4625-8447-624FC70F9D76 Q38730590-06097F80-2DC1-4AA9-B78F-F43EC1C262CA Q38795560-08FED25A-56AD-490C-9FBE-8A1DF6A1BE86 Q38919780-3463E127-47FE-487F-A58E-B0172106B8C4 Q39431314-84DB801A-970B-496F-802D-1E26AF2A5F8C Q41716558-9FB9F299-A826-43C1-91B2-1C09DF33DEC2 Q42135817-37175F1D-B78C-499C-9C82-474C5A78FFFD Q42321511-CFF0430D-F151-409D-B4BF-EA9C265BC925 Q44676922-F480DA50-4DA4-4018-B61F-FDFCD7A98CD5 Q46493299-E8AB6E84-E9B5-4CA4-AD56-1B1ED30A9A25 Q47259379-8A6F4470-8CE3-466F-BC16-D06C7A7C3494 Q47563547-126E5474-6044-4762-8F26-6439BFC09F1F Q47861428-DC66BD1F-4D36-4569-AE46-FB4626B72110 Q48110513-9A8E0E49-0814-41ED-B89B-D20E9BC5EAFB Q48194472-7275442B-86A2-4BC8-8C94-E2F9F7757940 Q48257941-049DFEDB-0CD3-40C3-BFC7-59A092F3527C Q49953442-555C2E19-324B-4B11-99BE-5A77B2D9850F Q50203117-32EAC726-E6E0-489A-B0EA-0AED45F6112D Q50420907-0A82974C-C737-4A59-9A7B-625B82C369B1 Q51751201-802D724A-8645-49AF-932A-EC945690929A Q52568014-8D3559A0-3BFB-49A2-8B4A-8226A0E86E1A Q52649233-CCA5FE5B-01D0-4F20-94F1-7482FBD7042B Q52841133-4C001C43-7BB3-46D8-BCD3-5101AE1085D8 Q54120492-33E5394A-6832-4496-A678-B660FC729343 Q54976476-EDCC493F-8303-489B-9FFF-C12B4849BC0B Q54987382-CE5D3EF7-3834-4366-AD31-D25DD7C3BCFE Q55024961-2426FFD2-22F2-47DB-A30C-A59A3BB453C0 Q55244223-EC87053B-1544-4D89-9D73-898260223CCE Q55474543-CBC528EB-DDE1-4D21-8F09-E2ADE99B5A4F Q55491411-9E4FB36E-FFC2-408D-A094-6FA3C4B5F3A1 Q56334475-391D13D0-235E-49D9-9540-3427B133C549 Q58777826-D12BAB3C-B9AA-4D97-A6EB-4535C89044D2

P2860

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

http://www.wikidata.org/entity/Q38892734

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Phase III Study of Cabozantini ...... tant Prostate Cancer: COMET-1.

@en

type

label

Phase III Study of Cabozantini ...... tant Prostate Cancer: COMET-1.

@en

prefLabel

Phase III Study of Cabozantini ...... tant Prostate Cancer: COMET-1.

@en

P1433

Q38892734-821311A5-559A-4C53-B7F9-3782E65125DB

P1476

Q38892734-2A82C5FA-7535-4B61-81D6-80B393E0F793

P2093

Q38892734-03F83C64-CE43-4C09-8E1E-420509D4B655

Q38892734-223D5A99-DFB1-418F-A5E8-BE4A33436B84

Q38892734-260789F7-3862-4DA9-AE30-A4891774419B

Q38892734-28826176-9C12-45A2-8002-793ECEA57F26

Q38892734-35A9911B-6176-4D46-A092-99F41B5125B4

Q38892734-4E207188-30F2-4513-9B9A-307BFD5B7220

Q38892734-521E16A3-1850-457A-AFEC-413CE5127DB1

Q38892734-59E0A914-906C-4ABD-8659-980C34BC0A2F

Q38892734-5C88B1D7-95A6-412E-AAF7-699150C64894

Q38892734-671B5102-1AC6-4EA1-8419-A9754F9C3CAE

P304

Q38892734-D149A141-74CC-4FB8-AA73-129FDC2E77BD

P31

Q38892734-E25FC92F-8C29-4E07-8C88-819AB023A7C9

P356

Q38892734-93ABC68A-A370-4ED0-B43C-18096DC11A82

P407

Q38892734-2FC626A3-A2A1-41B2-A301-8D2407A33241

P433

Q38892734-E0B76AFB-3813-4119-A6AE-7093E8666127

P478

Q38892734-A4E20617-ACBE-4A3A-830E-67C70C61E4BD

P50

Q38892734-B5CF0657-784C-4D4D-A968-481A97562F9A

Q38892734-DED03F00-6529-46E7-8822-8A71406678E4

Q38892734-ECC8DF7D-D0E0-4606-81B0-173616349B7A

P577

Q38892734-91F4E950-42A7-4C2E-BFB8-A8C5E1193D98

P698

Q38892734-51FA8F2E-2870-43B3-A13C-C1BB7A29117D

P356

JCO.2015.65.5597

P1433

Journal of Clinical Oncology

P1476

Phase III Study of Cabozantini ...... stant Prostate Cancer: COMET-1

@en

P2093

Aaron Weitzman

http://www.w3.org/2001/XMLSchema#string

Andries Bergman

http://www.w3.org/2001/XMLSchema#string

Arnulf Stenzl

http://www.w3.org/2001/XMLSchema#string

Colin Hessel

http://www.w3.org/2001/XMLSchema#string

Cora Sternberg

http://www.w3.org/2001/XMLSchema#string

David Ramies

http://www.w3.org/2001/XMLSchema#string

Elaine Lam

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Giorgio Cruciani

http://www.w3.org/2001/XMLSchema#string

Johann De Bono

http://www.w3.org/2001/XMLSchema#string

P304

3005-3013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.65.5597

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Michael Krainer

Antoine Thiery-vuillemin

Syed A. Hussain

P577

2016-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27400947

http://www.w3.org/2001/XMLSchema#string